Carboxy Or Salt Thereof Only Attached Indirectly To The Benzene Ring Patents (Class 514/570)
  • Patent number: 10238640
    Abstract: An aqueous oral liquid pharmaceutical composition system with reduced propensity for agglomeration and phase separation which is particularly amendable to the suspension of one or more pharmaceutical actives that are substantially insoluble in water. The oral liquid pharmaceutical composition may further comprise pharmaceutical actives that are soluble in water and dissolve in the aqueous medium. In the composition of the invention both suspended and any dissolved active agents are distributed homogeneously.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: March 26, 2019
    Assignee: Wyeth LLC
    Inventors: Jay Dickerson, William Mark, Annabelle Trimmer, David Jaeger, Amanda Alley
  • Patent number: 10016388
    Abstract: An ophthalmic lens or an intraocular lens releasing anthocyanin for the benefit of a user's eyes includes a matrix and anthocyanin dispersed in the matrix. An ophthalmic lens package includes a lens protection solution and the ophthalmic lens, the ophthalmic lens is immersed in the lens protection solution.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: July 10, 2018
    Assignee: HON HAI PRECISION INDUSTRY CO., LTD.
    Inventor: Hsiu-Wen Chien
  • Patent number: 9994901
    Abstract: Treatment and diagnostic methods are provided for pulmonary disease, including chronic obstructive pulmonary disease. Various pro-inflammatory mediators are elevated in a model of COPD that can be used predict the presence of COPD and/or subtypes of COPD in human patients. Profiles of these mediators can also predict the responsiveness of some patients to certain therapies, including thromboxane receptor antagonist treatment. Methods are provided for diagnosing a subject as a pulmonary disease candidate that include determining leukocyte expression in the subject of at least one pro-inflammatory mediator and identifying the subject as a pulmonary disease candidate when leukocyte expression in the subject of the pro-inflammatory mediator is increased compared to leukocyte expression of the pro-inflammatory mediator in a healthy individual. The pulmonary disease candidate can also be treated by administering a therapeutically effective amount of a thromboxane receptor antagonist.
    Type: Grant
    Filed: April 9, 2013
    Date of Patent: June 12, 2018
    Assignees: NATIONAL JEWISH HEALTH, A NON-PROFIT ORGANIZATION, THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: John M. Hartney, Raul M. Torres, Roberta Pelanda
  • Patent number: 9949940
    Abstract: A pharmaceutical composition as a solid oral dosage form is described, comprising: i) a combination of two pharmacological active principles, dexketoprofen salt with an organic or inorganic base and tramadol salt with an organic or inorganic acid, wherein: the organic or inorganic base is selected in the group: trometamol, trimethylamine, dimethylamine, ethylamine, triethylamine, diethylamine, L-lysine, L-arginine, diethanolamine, sodium hydroxide, calcium hydroxide the organic or inorganic acid is selected in the group: hydrochloric, hydrobromic, phosphoric, sulfuric, methanesulfonic, benzenesulfonic, toluenesulfonic, acetic, propionic, malic, maleic, succinic, citric, L-tartaric, lactic, malonic, aspartic, glutamic; ii) microcrystalline cellulose as a filler; iii) a binder selected in the group: maize starch, pre-gelatinized maize starch, hypromellose or their mixtures; iv) pharmaceutically acceptable excipients.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: April 24, 2018
    Assignee: Labortorios Mena Rini SA
    Inventors: Reinhard Schmitz, Tobias Kohl
  • Patent number: 9856634
    Abstract: A pull-out wand is disclosed for use with a water delivery device. The pull-out wand may include one or more sensors, such as a touch sensor and/or a proximity sensor.
    Type: Grant
    Filed: December 31, 2015
    Date of Patent: January 2, 2018
    Assignee: Delta Faucet Company
    Inventors: Robert W. Rodenbeck, Anthony G. Spangler, Michael J. Veros, Paul D. Koottungal
  • Patent number: 9849080
    Abstract: A transdermal composition comprising ibuprofen or salts thereof and a gelling agent which can be used for the treatment of such disorders as pain, inflammation, arthritis, muscle spasm and associated symptoms in humans and animals.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: December 26, 2017
    Assignee: Aponia Laboratories, Inc.
    Inventors: Haigang Chen, Gareth Winckle, Christopher Riley
  • Patent number: 9737500
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: August 22, 2017
    Assignee: Infirst Healthcare Limited
    Inventors: Robin M. Bannister, John Brew
  • Patent number: 9730442
    Abstract: The present invention relates to the use of 4-phenylbutyric acid, or one of the salts thereof, for improving the resistance of plants to harmful biological organisms, in particular to bacteria, viruses and nematodes, and for inhibiting hypersensitive cell death induced by such harmful biological organisms. The present invention also relates to the use of 4-phenylbutyric acid, or one of the salts thereof, as an antimicrobial agent for preventing or treating plant diseases caused by phytopathogens.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: August 15, 2017
    Assignee: INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT (IRD)
    Inventors: Jean-Luc Cacas, Antony Champion
  • Patent number: 9724322
    Abstract: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: August 8, 2017
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Gee-Hong Kuo, Rui Zhang, Aihua Wang, Alan R. DeAngelis
  • Patent number: 9668986
    Abstract: It is the object of the present invention a composition containing an N-acyl-ethanolamine in a solubilized form, particularly a solution for ophthalmic, intra-articular or intravesical use. Particularly, the present invention relates to a water-soluble composition comprising one or more N-acylethanolamines (NAE) in the form of an inclusion complex in methyl-beta-cyclodextrin (M?CD).
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: June 6, 2017
    Assignee: EPITECH GROUP S.R.L.
    Inventors: Francesco Della Valle, Sebastiano Mangiafico, Maria Federica Della Valle
  • Patent number: 9649278
    Abstract: An injection-molded shell of a dosage form of good quality is producible by a) providing a composition comprising i) from 25 to 90 weight percent of ethylcellulose, ii) from 7.5 to 60 weight percent of a polysaccharide or polysaccharide derivative being different from ethylcellulose, and iii) from 2.5 to 50 weight percent of at least one component being different from polysaccharides and polysaccharide derivatives, based on the total weight of the composition, with the proviso that the composition comprises zero or not more than 10 weight percent of gelatin and zero or not more than 10 weight percent of a polymer comprising homo- or copolymerized acrylic acid, homo- or copolymerized methacrylic acid, a homo- or copolymerized acrylate or a homo- or copolymerized methacrylate, and b) subjecting the composition to shearing and heat to plasticize the composition and injection-molding the plasticized composition into a three-dimensional shell of a dosage form.
    Type: Grant
    Filed: October 9, 2012
    Date of Patent: May 16, 2017
    Inventors: Michael D. Read, Karen A. Coppens, Mark J. Hall, Jin Zhao
  • Patent number: 9579291
    Abstract: The present invention relates to carriers for the controlled release of active agents, comprising a core, comprising surface reacted natural or synthetic calcium carbonate, and at least one active agent, wherein said at least one active agent is associated with said natural or synthetic surface-reacted calcium carbonate, and wherein said surface-reacted natural or synthetic calcium carbonate is a reaction product of natural or synthetic calcium carbonate with carbon dioxide and one or more acids, wherein the carbon dioxide is formed in situ by the acid treatment and/or is supplied from an external source, and a coating encapsulating the core. It furthermore relates to the preparation of loaded carriers, as well as their use in different applications.
    Type: Grant
    Filed: November 8, 2012
    Date of Patent: February 28, 2017
    Assignee: Omya International AG
    Inventors: Patrick Schwarzentruber, Nicola Di Maiuta, Joachim Schoelkopf, Catherine Jean Ridgway, Patrick A. C. Gane
  • Patent number: 9527793
    Abstract: Disclosed herein are compounds and compositions useful for reducing the risk of infection. In particular, disclosed herein are mandelic acid condensation polymers, compositions comprising such compounds, processes for producing such compounds, and methods of using such compounds.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: December 27, 2016
    Assignees: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, RUSH UNIVERSITY MEDICAL CENTER
    Inventors: Robert A. Anderson, Jr., Xiao-Hui Diao, Lourens J. D. Zaneveld, Calvin J. Chany, II, Aleksej Krunic, Donald P. Waller, Duane L. Venton, Sanjay Jain
  • Patent number: 9475747
    Abstract: The disclosures herein provide compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI and Formula VII or its pharmaceutical acceptable compositions and salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. The pharmaceutical compositions may be formulated for oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, nanoparticle, buccal administration or transdermal administration. Such compositions may be used to treatment of urea cycle disorders and gout or its associated complications.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: October 25, 2016
    Inventor: Mohan Murali Alapati
  • Patent number: 9346742
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of fibromyalgia pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, post herpetic neuralgia, diabetic neuropathy, bipolar depression, stress, cancer pain, and lower back pain.
    Type: Grant
    Filed: February 10, 2013
    Date of Patent: May 24, 2016
    Assignee: CELLIX BIO PRIVATE LIMITED
    Inventor: Mahesh Kandula
  • Patent number: 9290428
    Abstract: The present invention relates to a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R represents one or more groups independently selected from fluorine, chlorine, bromine, and iodine, said process comprising the cyclopropanation of a compound of formula (II) with ethylene carbonate or ethylene sulfate: wherein X is chlorine, bromine, iodine or a triflate group (CF3SO3) or a group wherein R is as defined above and G is —CN or —COOR2 wherein R2 is a C1-C4 straight or branched alkyl chain.
    Type: Grant
    Filed: June 23, 2014
    Date of Patent: March 22, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Massimo Verzini, Livius Cotarca, Alberto Guidi, Alfonso Melloni, Paolo Maragni
  • Patent number: 9211251
    Abstract: Injectable formulations of water-soluble salts of diclofenac, which cause significantly less pain at the site of injection and can be administered by intradeltoid route, in addition to intragluteal and slow intravenous route.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: December 15, 2015
    Assignee: TROIKAA PHARMACEUTICALS LIMITED
    Inventors: Ketan Rajnibhai Patel, Milan Rajnibhai Patel
  • Patent number: 9205054
    Abstract: A process for producing a solubilized ibuprofen, preferably in the form of a granulate, the process comprising the steps of: providing a mixture comprising solid ibuprofen and a first base selected from the group consisting of sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium glycinate, potassium glycinate and tribasic sodium and potassium phosphates and mixtures thereof, and reacting the ibuprofen and the first base in essentially dry state. The obtainable granulate and the pharmaceutical compositions and dosage forms that may be produced therefrom are distinguished by their high solubility and rapid disintegration and dissolution in aqueous media, by their good flow properties and compressibility, by rapidly achieving onset of analgesic effect.
    Type: Grant
    Filed: March 22, 2006
    Date of Patent: December 8, 2015
    Assignee: LOSAN PHARMA GMBH
    Inventors: Peter Gruber, Wolfgang Mohr
  • Patent number: 9186333
    Abstract: The present invention provides a process for preparing a pharmaceutical composition of fingolimod comprising: (i) obtaining a intimate admixture comprising fingolimod or a pharmaceutically acceptable salt thereof, and at least one surfactant (wetting agent), e.g., an intimate admixture of the fingolimod and the at least one surfactant, and (ii) optionally combining the intimate admixture from step (i) with one or more excipients. Also provided are pharmaceutical compositions and dosage forms obtainable by the process, uses of the pharmaceutical compositions and dosage forms, and methods of treating appropriate diseases with the pharmaceutical compositions or dosage forms.
    Type: Grant
    Filed: August 1, 2012
    Date of Patent: November 17, 2015
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventor: Julia Hrakovsky
  • Patent number: 9180107
    Abstract: Provided herein are compositions and methods for treating cancer by increasing the inhibitory effect of cetuximab on HIF1? expression by administering cetuximab in combination with anti-angiogenic thyroid hormone analogs such as tetrac or triac.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: November 10, 2015
    Assignee: NANOPHARMACEUTICALS LLC
    Inventors: Hung-Yun Lin, Faith B. Davis, Paul J. Davis, Shaker A. Mousa
  • Patent number: 9174916
    Abstract: The present invention provides compounds, and compositions comprising these compounds, which have immunomodulatory activity and/or anti-inflammatory activity.
    Type: Grant
    Filed: February 18, 2013
    Date of Patent: November 3, 2015
    Assignees: VERSITECH LIMITED, BAGI RESEARCH LIMITED
    Inventors: Allan Sy Lau, Lai Hung Cindy Yang, Chi Chung Stanley Chik, Chun Bong James Li
  • Patent number: 9138404
    Abstract: Methods of treating at least one condition chosen from pain, inflammation, and fever in a critically ill patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen using a first dosage regimen, wherein the first dosage regimen produces a first pharmacokinetic profile in critically ill patients that is about equivalent to a second pharmacokinetic profile produced by administration of the intravenous pharmaceutical composition using a second dosage regimen of ibuprofen to non-critically ill patients, wherein the at least one condition of the critically ill patient is thereby treated.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: September 22, 2015
    Assignee: Cumberland Pharmaceuticals Inc.
    Inventors: Leo Pavliv, Amy Dix Rock
  • Patent number: 9132108
    Abstract: The present invention provides a pharmaceutical composition for ameliorating and/or preventing leptin resistance. The pharmaceutical composition of the present invention contains flurbiprofen.
    Type: Grant
    Filed: April 14, 2010
    Date of Patent: September 15, 2015
    Assignee: HIROSHIMA UNIVERSITY
    Inventors: Toru Hosoi, Koichiro Ozawa
  • Patent number: 9114068
    Abstract: Methods of treating a patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen in an amount effective to treat at least one condition in the patient chosen from pain, inflammation, and fever and to provide a clinically relevant effect on mean arterial pressure of the patients during the dosage interval comprising no increase or no statistically significant increase in mean arterial pressure.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: August 25, 2015
    Assignee: Cumberland Pharmaceuticals, Inc.
    Inventors: Leo Pavliv, Amy Dix Rock
  • Publication number: 20150148325
    Abstract: The invention provides extended release pro-liposomal, non-aqueous, pharmaceutical formulations of a hydrophobic active pharmaceutical ingredient (API) of low water solubility but readily dissolved in alcohols and methods for making same. The formulations can be administered by infiltration into an incision, or by injection.
    Type: Application
    Filed: May 9, 2013
    Publication date: May 28, 2015
    Inventors: Shimon Amselem, Michael Naveh
  • Publication number: 20150147281
    Abstract: Provided are methods, test devices, and diagnostic kits for predicting, assessing, and diagnosing the risk of a disease using salivary analysis. The methods comprise providing a whole (unfractionated) saliva sample from a subject; contacting an aliquot of the saliva with two or more lectins under conditions that allow the two or more lectins to bind to a lectin-binding component of the saliva; detecting the amount of bound lectin; and comparing the amount of bound lectin to the amount known to bind a saliva sample from a control patient, to predict the risk of a disease in the subject. Also provided are methods for reducing the risk of a disease and a method for assessing the risk of the disease at a defined level.
    Type: Application
    Filed: November 17, 2014
    Publication date: May 28, 2015
    Inventors: Patricia A. Denny, Paul C. Denny, Mahvash Navazesh
  • Publication number: 20150148355
    Abstract: A silicone gel (“silogel”) composition used to deliver pharmaceutical products transdermally as well as a method for producing the silogel composition, which may contain up to 80% additive ingredients. Preferred embodiments of the invention may include silogel compositions which provide high viscosity/no separation due to API. They are not temperature-sensitive, have no shear stress from the ointment mill/EMP, have no gumming up/stickiness, and no hardening.
    Type: Application
    Filed: November 24, 2014
    Publication date: May 28, 2015
    Inventor: John Olin Trimble
  • Publication number: 20150141389
    Abstract: The present disclosure relates to a semi-solid topical drug delivery formulation including a silicone-based excipient, at least one volatile solvent, at least one active configured to be topically delivered through a patient's skin for an intended therapeutic application, and at least one enhancer. The formulation may additionally optionally include at least one agent that provides occlusivity when the formulation is applied onto a patient's skin. The at least one active may be a healthcare and/or pharmaceutical active.
    Type: Application
    Filed: March 11, 2013
    Publication date: May 21, 2015
    Inventors: Hyder Aliyar, Robert Huber, Gary Loubert, Gerald Schalau
  • Publication number: 20150139934
    Abstract: A method for screening a patient for angioinhibition resistance and treating said patient having a disease susceptible to treatment via an anti-angiogenic agent. The screening method includes an assay for identifying the presence of angioinhibition resistance in patients by collecting patient blood or serum and subjecting it to a Chick Chorioallantoic Membrane (CAM) angiogenesis assay configured for accepting a human tumor wherein the human tumor xenograft includes a vasculature system. The screening method and assay further includes steps that include using the CAM results for identifying the endogenous pro-angiogenic non-peptide hormone concentrations of the blood sample by calculating the vascular activity of the vasculature system of the human tumor xenograft in the presence of anti-angiogenic drugs and inducing in the patient, a state of subclinical hypothyroidism prior to commencing anti-angiogenic treatment.
    Type: Application
    Filed: November 18, 2014
    Publication date: May 21, 2015
    Inventors: SHAKER A. MOUSA, PAUL J. DAVIS
  • Publication number: 20150140133
    Abstract: A system is described for long-term controlled release delivery of a drug or a therapeutic agent. According to the invention, one or more drugs or therapeutic agents contained in microspheres are mixed with a temperature sensitive hydrogel which is then introduced directly to the desired situs of the drug or therapeutic agent. The temperature sensitive hydrogel may also contain a drug or a therapeutic agent, for example, a pain relieving drug, for a short-term controlled release. The temperature sensitive hydrogel is in liquid state at room temperature, but upon injection, shortly becomes gelatinous. This system is particularly suitable for treatment of diseases, disorders, or conditions, for example, tumors, discogenic back pain, or arthritis, warranting localized administration of a drug or a therapeutic agent. In addition, the specification provides a method for production of a drug- or therapeutic agent-containing microspheres.
    Type: Application
    Filed: December 4, 2014
    Publication date: May 21, 2015
    Inventor: Tae-Hong Lim
  • Publication number: 20150141476
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, rosacea.
    Type: Application
    Filed: January 23, 2015
    Publication date: May 21, 2015
    Inventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
  • Publication number: 20150132385
    Abstract: The present invention relates to nanocrystalline solid dispersion compositions having discrete particles, wherein each discrete particle comprises crystals of at least one pharmaceutical active; veterinary active; nutraceutical active dispersed in the matrix of at least one crystallization inducer and/or coexisting with crystals of crystallization inducer, optionally along with pharmaceutically acceptable excipients. The present invention also encompasses a novel one-step process for generation of nanocrystalline solid dispersions. The present invention is particularly of use for improving the dissolution of pharmaceutical actives, veterinary actives; nutraceutical actives exhibiting dissolution-limited bioavailability. Dissolution enhancement is because of the decreased crystallite size of the pharmaceutical active.
    Type: Application
    Filed: March 7, 2013
    Publication date: May 14, 2015
    Inventors: Arvind Kumar Bansal, Ajay Kumar Raju Dantuluri, Shete Ganesh Bhaskarao, Pawar Yogesh Bapurao
  • Patent number: 9028869
    Abstract: The present invention is a solid dosage form for oral administration of ibuprofen comprising a modified release formulation of ibuprofen which provides an immediate burst effect and thereafter a sustained release of sufficient ibuprofen to maintain blood levels at least 6.4 ?g/ml over an extended period of at least 8 hours following administering of a single dose.
    Type: Grant
    Filed: February 16, 2010
    Date of Patent: May 12, 2015
    Assignee: Shasun Pharmaceuticals Limited
    Inventors: Michael Hite, Cathy Federici, Alan Brunelle, Stephen Turner
  • Publication number: 20150126481
    Abstract: The present disclosure is drawn to an adhesive peel-forming formulation for dermal delivery of a drug, comprising a drug, a solvent vehicle, and a polymer peel-forming agent. The solvent vehicle can comprise a volatile solvent system comprising one or more volatile solvent, and a non-volatile solvent system comprising two or more non-volatile solvents. The non-volatile solvent system can have a solubility with respect to the drug that is within a window of operable solubility such that the drug is deliverable at therapeutically effective rates over a sustained period of time.
    Type: Application
    Filed: November 5, 2014
    Publication date: May 7, 2015
    Inventors: Jie Zhang, Kevin S. Warner, Michael A. Ashburn, Larry D. Rigby, Suyi Niu
  • Patent number: 9023892
    Abstract: A compound for use as an antimicrobial having a formula (A).
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: May 5, 2015
    Inventors: Allan James McKinley, Thomas V. Riley, Nigel Lengkeek, Scott Stewart, Ramiz Boulos
  • Publication number: 20150118303
    Abstract: Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.
    Type: Application
    Filed: November 12, 2014
    Publication date: April 30, 2015
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
  • Patent number: 9018193
    Abstract: Novel water stable pharmaceutical compositions, their liquid form oral pharmaceutical compositions and kits thereof, rehydration beverages containing these water stable pharmaceutical compositions methods of manufacture and methods of use thereof are disclosed. The novel aqueous delivery systems are useful, inter alia, as alternative pharmaceutical dosing agents to tablets, capsules and other forms of delivering medication to a mammalian host in need thereof.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: April 28, 2015
    Assignee: Bev-Rx, Inc.
    Inventor: Kyle A. Reed
  • Publication number: 20150110852
    Abstract: A system for dermal delivery of lidocaine, bupivacaine, diclofenac, or ketoprofen is provided which comprises at least two components, for example, a sheet of a solid and flexible material, and a vehicle liquid comprising a solvent and optionally other ingredients. A drug, selected from group consisting of lidocaine, bupivacaine, diclofenac, and ketoprofen, can be impregnated in the sheet or contained in the vehicle liquid. These two components can be stored separately and joined either shortly before or at the time of application. To use the system, the vehicle liquid may be applied either on the target skin area or on the sheet, and the sheet may then be applied on the target skin area so that the vehicle liquid is positioned between the sheet and the skin and brought into contact with the ingredients impregnated in the sheet.
    Type: Application
    Filed: May 8, 2013
    Publication date: April 23, 2015
    Inventor: Jie Zhang
  • Publication number: 20150111749
    Abstract: Methods and compositions for controlling plant pests, particularly weeds and/or plant phytopathogens using sarmentine and/or analogs thereof are disclosed.
    Type: Application
    Filed: December 31, 2014
    Publication date: April 23, 2015
    Inventors: Huazhang Huang, Ratnakar Asolkar
  • Patent number: 9012508
    Abstract: An effective dose of intravenous ibuprofen administered every 6 hours in surgery patients is a safe and effective way to reduce both pain and the need for morphine. In preferred embodiments, the administration of intravenous ibuprofen starts with the onset of anesthesia.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: April 21, 2015
    Assignee: Cumberland Pharmaceuticals
    Inventor: Leo Pavliv
  • Publication number: 20150105468
    Abstract: The present invention relates to a pharmaceutical composition of ibuprofen and tramadol for ophthalmic use. Said composition is effective and safe for the treatment of ocular inflammation and/or pain associated to different diseases or pathological states which affect the eye area In particular, the ophthalmic composition of the invention is indicated, for example, for the treatment of pain and/or inflammation after eye surgery.
    Type: Application
    Filed: October 10, 2014
    Publication date: April 16, 2015
    Inventors: Fernando Martinez-Alzamora, Jose Miguel Rizo Martinez, Antonia Gomez Calvo, Nuria Sanz Menendez, Angel Munoz Ruiz
  • Publication number: 20150105338
    Abstract: The invention provides compositions comprising a therapeutically effective amount of a compound of general formula (I): wherein R1, R2 and R3 may be independently selected from H, OH and OMe; wherein X is C1 or C2 and wherein for C2 each carbon is linked by a single or multiple bond (preferably a double bond) and is substituted with one or more H or OH, for use as a medicament for treating or preventing the development of medical conditions characterised by inappropriate platelet aggregation. The compositions of the invention may be used to maintain heart health by reducing platelet aggregation; benefit the circulation; and/or normalize or otherwise benefit blood flow.
    Type: Application
    Filed: July 17, 2014
    Publication date: April 16, 2015
    Applicant: PROVEXIS NATURAL PRODUCTS LIMITED
    Inventor: Niamh O'Kennedy
  • Publication number: 20150105315
    Abstract: The present invention relates to polypeptide fragments comprising an amino-terminal fragment of the PA subunit of a viral RNA-dependent RNA polymerase or variants thereof possessing endonuclease activity, wherein said PA subunit is from a virus belonging to the Orthomyxoviridae family. This invention also relates to (i) crystals of the polypeptide fragments which are suitable for structure determination of said polypeptide fragments using X-ray crystallography and (ii) computational methods using the structural coordinates of said polypeptide to screen for and design compounds that modulate, preferably inhibit the endonucleolytically active site within the polypeptide fragment. In addition, this invention relates to methods identifying compounds that bind to the PA polypeptide fragments possessing endonuclease activity and preferably inhibit said endonucleolytic activity, preferably in a high throughput setting.
    Type: Application
    Filed: October 21, 2014
    Publication date: April 16, 2015
    Applicants: EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL), UNIVERSITY JOSEPH FOURIER FILIALE, Centre National de la Recherche Scientifique - Direction de la Politique Industrielle
    Inventors: Denis Bouvier, Thibaut Crepin, Rob Ruigrok, Alexander Dias, Stephen Cusack
  • Publication number: 20150105469
    Abstract: The present disclosure provides novel methods for determining an effective dosage of a PAA prodrug and for treating a UCD that incorporate body surface area and urinary PAGN concentration. The disclosure further provides novel methods for assessing compliance with PAA prodrug administration that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, or age. The disclosure further provides novel methods of treating a UCD in a subject in need thereof that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, and/or age.
    Type: Application
    Filed: October 14, 2014
    Publication date: April 16, 2015
    Inventors: Bruce SCHARSCHMIDT, Masoud MOKHTARANI
  • Publication number: 20150094372
    Abstract: The present invention relates to substituted aromatic compounds of Formula I and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds in the prevention and/or treatment of various diseases and conditions in subjects, including the prevention or treatment of (i) blood disorders, (ii) renal disorders, a nephropathies, or renal disorder complications; (iii) inflammatory-related diseases; and/or (iv) oxidative stress related disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: April 2, 2015
    Inventors: Boulos ZACHARIE, Christopher PENNEY, Lyne GAGNON, Jean-Francois BIENVENU, Valérie PERRON, Brigitte GROUIX
  • Publication number: 20150093439
    Abstract: The present invention is directed to a dosage form comprising an immediate release portion of a first active pharmaceutical ingredient and a delayed release portion of a second active pharmaceutical ingredient wherein (a) the immediate release portion comprises from about 1 mg to about 1000 mg of the first active pharmaceutical ingredient; and (b) the delayed release portion comprises from about 1 mg to about 1000 mg of the second active pharmaceutical ingredient; wherein the delayed release portion is coated with a delayed release coating comprising at least one swellable erodible polymer and a filler, and wherein the immediate release portion is in contact with the delayed release coating.
    Type: Application
    Filed: September 26, 2014
    Publication date: April 2, 2015
    Inventors: Der-Yang Lee, Shun-Por Li, Timothy Kutch
  • Publication number: 20150086565
    Abstract: Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyses of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.
    Type: Application
    Filed: March 14, 2013
    Publication date: March 26, 2015
    Applicants: Massachusetts Institute of Technology, The General Hospital Corporaiton d/b/a Massachusetts General Hospital, The Broad Institute, Inc.
    Inventors: Richard O. Hynes, Alexandra Naba, Karl Clauser, Steven A. Carr, Kenneth Tanabe
  • Publication number: 20150087705
    Abstract: Disclosed herein are compounds, compositions and methods for preventing and treating diseases such as intracerebral hemorrhage, cancer, or conditions associated with damaged cells, activated lymphocytes, or microbial products. The disclosed compounds are curcumin analogs. The curcumin analogs possess anti-inflammatory and antioxidant properties, which in part, reduce AP-1 and NF-?B activity.
    Type: Application
    Filed: September 22, 2014
    Publication date: March 26, 2015
    Inventors: Cargill H. Alleyne, JR., Krishnan M. Dhandapani, Ken Wen, MingLiang Ma, WenJing Hu
  • Publication number: 20150087710
    Abstract: Methods of treating at least one condition chosen from pain, inflammation, and fever in a critically ill patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen using a first dosage regimen, wherein the first dosage regimen produces a first pharmacokinetic profile in critically ill patients that is about equivalent to a second pharmacokinetic profile produced by administration of the intravenous pharmaceutical composition using a second dosage regimen of ibuprofen to non-critically ill patients, wherein the at least one condition of the critically ill patient is thereby treated.
    Type: Application
    Filed: October 6, 2014
    Publication date: March 26, 2015
    Inventors: Leo Pavliv, Amy Dix Rock
  • Patent number: 8986735
    Abstract: A solid dosage form containing a taste masked active agent is provided. The solid dosage form may be provided as a water soluble film that is disintegrable in the oral cavity to deliver and release the taste masked active agent. The disintegrable film includes at least one water soluble polymer and a taste masked ketoprofen active. Also provided are methods for preparing the solid dosage form and for using the solid dosage to administer an effective dosage of an active agent, such as ketoprofen, into the oral cavity for absorption.
    Type: Grant
    Filed: March 15, 2007
    Date of Patent: March 24, 2015
    Assignee: Novartis AG
    Inventors: Alexander M Schobel, Shyam S Vangala